AMT raises €22M in first round

Anyone looking for fresh evidence about gene therapy's allure to investors should check out today's announcement that Amsterdam Molecular Therapeutics has raised €22 million in its first round of venture capital. ABN AMRO Capital/Life Sciences, Advent Venture Partners, Gilde Healthcare Partners and Crédit Agricole Private Equity put up the money to fund AMT's work in gene therapy. Their money will go to advancing AMT-011--AMT's lead product intended to treat lipoprotein lipase deficiency--from Phase II through to registration. AMT was founded in 1998.

"The financing provides AMT with a solid foundation on which the company can grow its core business on an accelerated timetable. AMT can now unlock the potential of its R&D pipeline, and provide patients suffering from serious orphan diseases, caused by a monogenetic defect, a fundamental cure," said Ronald H.W. Lorijn, MD, PhD, M.B.A., the CEO of AMT.

- here's the release on the new funding round

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.